×

Factbox-US drugmakers turn to China for licensing deals

By Thomson Reuters Sep 28, 2026 | 9:39 AM

Sept 28 (Reuters) – Merck on Monday agreed to pay Chinese ​biotech SciBrunch Therapeutics $400 ‌million upfront for global rights to an experimental cancer drug, ‌making ​it ⁠the latest US ⁠drugmaker to license China-developed medicines.

Chinese biotechs often retain domestic ​rights and license their drugs ⁠overseas in ⁠exchange for upfront ​and milestone payments ​as well as royalties.

Some ‌major deals are listed below:

Date US Chinese Deal Assets/pro Upfro Potentia

company company type grams nt l value

value

Septem Merck SciBrunc Licens SPR2015, $400 Up to

ber h ing experiment milli $2.13

2026 Therapeu al cancer on billion

tics drug

May Pfizer Innovent Licens 12 $650 Up ⁠to

2026 Biologic ing early-stag milli $10.5

s e oncology on billion

programs

May Bristol Jiangsu Licens 13 $600 Up to

2026 Myers Hengrui ing early-stag milli $15.2

Squibb Pharmace e programs on billion

uticals in

oncology,

hematology

and

immunology

Februa Eli Innovent Licens Experiment $350 Up to

ry Lilly Biologic ing al cancer milli $8.85

2026 s and on billion

immunology

drugs

Januar AbbVie RemeGen Licens RC148, $650 Up to

y 2026 ing experiment milli $5.6

al ⁠cancer on billion

drug

June Regener Hansoh Licens HS-20094/o $80 Up ‌to

2025 on Pharma ing latorepati milli $2.01

Pharmac de, on billion

eutical GLP-1/GIP

s obesity

drug

May Pfizer 3SBio Licens SSGJ-707, $1.25 Up to

2025 ing experiment billi $6.05

al cancer on billion,

drug not

includin

g

Pfizer’s

$100

million

equity

investme

nt

Decemb Merck Hansoh Licens HS-10535, $112 Up ⁠to $2

er Pharma ing oral milli billion

2024 weight-los on

s pill

Novemb Merck LaNova Licens LM-299, $588 Up ​to

er Medicine ing experiment milli $3.3

2024 s al ‌cancer on billion

drug

June AbbVie FutureGe Licens FG-M701, $150 Up to

2024 n ing experiment milli $1.71

Biopharm al on billion

aceutica inflammato

l ry bowel

disease

drug

Decemb Bristol Sichuan Licens BL-B01D1, $800 Up ​to

er Myers Biokin ing experiment milli $8.4

2023 Squibb Pharmace al on billion

utical antibody

/SystImm cancer

une drug

Decemb Summit Akeso Licens Ivonescima $500 Up to $5

er Therape ing b, milli billion

2022 utics experiment on

al ⁠cancer

therapy

(Reporting by Siddhi Mahatole and Kunal Das in Bengaluru; Editing by Sahal ​Muhammed)